Two-Step Cell Death Induction by the New 2-Arachidonoyl Glycerol Analog and Its Modulation by Lysophosphatidylinositol in Human Breast Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Date 2025 Jan 25

PMID 39859533

Authors

Mikhail G Akimov

Natalia M Gretskaya

Evgenia I Gorbacheva

Nisreen Khadour

Galina D Sherstyanykh

Vladimir V Bezuglov

Affiliations

Soon will be listed here.

Abstract

2-arachnadoyl glycerol (2-AG) is one of the most common endocannabinoid molecules with anti-proliferative, cytotoxic, and pro-proliferative effects on different types of tumors. Typically, it induces cell death via cannabinoid receptor 1/2 (CB1/CB2)-linked ceramide production. In breast cancer, ceramide is counterbalanced by the sphingosine-1-phosphate, and thus the mechanisms of 2-AG influence on proliferation are poorly understood. We evaluated the mechanism of the anti-proliferative action by 2-AG and the influence of lysophaosphatidylinositol (LPI) on it in six human breast cancer cell lines of different tumor degree (MCF-10A, MCF-7, BT-474, BT-20, SK-BR-3, and MDA-MB-231) using resazurin test, inhibitor, blocker, and anti-oxidant analysis, and siRNA interference. To avoid acyl migration in 2-AG, we replaced it with the analog 2-arachidonoyl-1,3-difluoropropanol (2-ADFP) newly synthesized by us. Using a molecular docking approach, we showed that at the CB2 receptor, 2-ADFP and 2-AG were very close to each other. However, 2-ADFP demonstrated a stronger affinity towards CB1 in the antagonist-bound conformation. 2-ADFP was anti-proliferative in all the cell lines tested. The toxicity of 2-ADFP was enhanced by LPI. 2-ADFP activity was reduced or prevented by the CB2 and vanilloid receptor 1 (TRPV1) blockers, inositol triphosphate receptor, CREB, and cyclooxygenase 2 inhibitor, and by anti-oxidant addition. Together with the literature data, these results indicate CB2- and TRPV1-dependent COX-2 induction with concomitant cell death induction by the oxidized molecule's metabolites.

References

Hassing H, Fares S, Larsen O, Pad H, Hauge M, Jones R . Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. Biochem Pharmacol. 2016; 119:66-75. DOI: 10.1016/j.bcp.2016.08.018. View

Maccarrone M, Finazzi-Agro A . The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ. 2003; 10(9):946-55. DOI: 10.1038/sj.cdd.4401284. View

Zhou X, Li J, Yang W . Calcium/calmodulin-dependent protein kinase II regulates cyclooxygenase-2 expression and prostaglandin E2 production by activating cAMP-response element-binding protein in rat peritoneal macrophages. Immunology. 2014; 143(2):287-99. PMC: 4172144. DOI: 10.1111/imm.12309. View

Erez-Roman R, Pienik R, Futerman A . Increased ceramide synthase 2 and 6 mRNA levels in breast cancer tissues and correlation with sphingosine kinase expression. Biochem Biophys Res Commun. 2009; 391(1):219-23. DOI: 10.1016/j.bbrc.2009.11.035. View

Goh J, Goh C, Lim Q, Zhang S, Koh C, Chiam K . Transcriptomics indicate nuclear division and cell adhesion not recapitulated in MCF7 and MCF10A compared to luminal A breast tumours. Sci Rep. 2022; 12(1):20902. PMC: 9719475. DOI: 10.1038/s41598-022-24511-z. View

Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J . High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 2016; 540(7634):602-606. PMC: 5433929. DOI: 10.1038/nature20613. View

Reyes-Resina I, Navarro G, Aguinaga D, Canela E, Schoeder C, Zaluski M . Molecular and functional interaction between GPR18 and cannabinoid CB G-protein-coupled receptors. Relevance in neurodegenerative diseases. Biochem Pharmacol. 2018; 157:169-179. DOI: 10.1016/j.bcp.2018.06.001. View

Omer S, Pathak S, Nadar R, Bowen D, Sandey M, Dhanasekaran M . Validating the anti-lymphoma pharmacodynamic actions of the endocannabinoids on canine non-Hodgkin lymphoma. Life Sci. 2023; 327:121862. DOI: 10.1016/j.lfs.2023.121862. View

Herrera B, Carracedo A, Diez-Zaera M, Gomez del Pulgar T, Guzman M, Velasco G . The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res. 2006; 312(11):2121-31. DOI: 10.1016/j.yexcr.2006.03.009. View

10.

Sanchez C, de Ceballos M, Gomez Del Pulgar T, Rueda D, Corbacho C, Velasco G . Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001; 61(15):5784-9. View

11.

Akimov M, Gretskaya N, Gorbacheva E, Khadour N, Chernavskaya V, Sherstyanykh G . The Interaction of the Endocannabinoid Anandamide and Paracannabinoid Lysophosphatidylinositol during Cell Death Induction in Human Breast Cancer Cells. Int J Mol Sci. 2024; 25(4). PMC: 10888638. DOI: 10.3390/ijms25042271. View

12.

Calvillo-Robledo A, Cervantes-Villagrana R, Morales P, Marichal-Cancino B . The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling. Life Sci. 2022; 301:120596. DOI: 10.1016/j.lfs.2022.120596. View

13.

Rakotoarivelo V, Mayer T, Simard M, Flamand N, Di Marzo V . The Impact of the CB Cannabinoid Receptor in Inflammatory Diseases: An Update. Molecules. 2024; 29(14). PMC: 11279428. DOI: 10.3390/molecules29143381. View

14.

Butt S, Badshah Y, Shabbir M, Rafiq M . Molecular Docking Using Chimera and Autodock Vina Software for Nonbioinformaticians. JMIR Bioinform Biotechnol. 2024; 1(1):e14232. PMC: 11168238. DOI: 10.2196/14232. View

15.

Ramer R, Wittig F, Hinz B . The Endocannabinoid System as a Pharmacological Target for New Cancer Therapies. Cancers (Basel). 2021; 13(22). PMC: 8616499. DOI: 10.3390/cancers13225701. View

16.

Rao M, Chen D, Zhan P, Jiang J . MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway. Biol Direct. 2019; 14(1):9. PMC: 6500002. DOI: 10.1186/s13062-019-0241-1. View

17.

Oka T, Sato K, Hori M, Ozaki H, Karaki H . Xestospongin C, a novel blocker of IP3 receptor, attenuates the increase in cytosolic calcium level and degranulation that is induced by antigen in RBL-2H3 mast cells. Br J Pharmacol. 2002; 135(8):1959-66. PMC: 1573325. DOI: 10.1038/sj.bjp.0704662. View

18.

Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M . Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 1999; 141(1):118-26. DOI: 10.1210/endo.141.1.7239. View

19.

Nithipatikom K, Endsley M, Isbell M, Falck J, Iwamoto Y, Hillard C . 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004; 64(24):8826-30. DOI: 10.1158/0008-5472.CAN-04-3136. View

20.

Nithipatikom K, Isbell M, Endsley M, Woodliff J, Campbell W . Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat. 2010; 94(1-2):34-43. PMC: 3039283. DOI: 10.1016/j.prostaglandins.2010.12.002. View